Topic: MS

Ponesimod – phase III results in MS

July 31, 2019  

¿Quién es más inerte?

July 24, 2019  

MS highlights from EAN 2019

July 10, 2019  

HSCT vs. drug in RRMS: head-to-head study

June 19, 2019  

Switching therapies in MS – what is the evidence?

May 28, 2019  

AAN 2019 DAILY REPORT

May 9, 2019  

Europe restricts alemtuzumab use for MS

May 1, 2019  

Secondary-progressive MS: conceptual and practical challenges

April 17, 2019  

Siponimod receives FDA approval for SPMS

March 29, 2019  

Polypharmacy common in MS patients

March 13, 2019